Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
α1-18-corticotropin is a synthetic analogue of adrenocorticotropic hormone (ACTH), specifically comprising the first 18 amino acids of the ACTH peptide, with D-serine at position 1, lysine at position 17, and lysine amide at position 18. It has been studied for its adrenocorticotrophic effects and demonstrates a prolonged duration of action compared to other ACTH analogues such as tetracosactrin depot. Unlike some depot formulations, its extended activity is attributed to decreased degradation in circulation rather than delayed release from the injection site. The compound is effective after intramuscular, subcutaneous, and even intranasal administration. Its mechanism involves agonism of the adrenocorticotropic hormone receptor on adrenal cortex cells, stimulating corticosteroid synthesis[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on α1-18-corticotropin.